🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Happy #LaborDay from all of us at Cerevance! Today, we celebrate the hard work, dedication, and passion of our incredible team. Your commitment drives our success and innovation every day. Thank you for all that you do!

September is World Alzheimer’s Month, and today we recognize #WorldAlzheimer’sDay. Throughout this month and beyond, we commend the resilience of individuals with #Alzheimer’sDisease as they navigate and overcome daily challenges.

Our CEO, Craig Thompson, will be joining a panel at the upcoming #FierceBiotechSummit to discuss the latest in CNS drug discovery. globenewswire.com/en/news-releas…

We've achieved our second milestone in our research collaboration with Merck and are excited by the advancements we’ve made in identifying potential novel therapeutic targets for patients with Alzheimer’s disease. Read the press release here: globenewswire.com/en/news-releas…

Our CEO, Craig Thompson, recently shared his insights during a panel at the #FierceBiotechSummit, where he discussed the future of #neuroscience innovation. We’re grateful for the opportunity to be a part of this important discussion. Learn more here: bit.ly/4eWEru7

Thrilled to welcome, Dr. Sarah Sheikh to our Board of Directors. Her deep expertise in #neuroscience will be an invaluable asset as we continue to advance our mission of transforming the standard of care for CNS disorders. globenewswire.com/en/news-releas…

We’re thrilled to announce the publication of our positive Phase 2 data from the clinical trial of solengepras for Parkinson’s disease in The Lancet's eClinicalMedicine. Check out the publication here: sciencedirect.com/science/articl…

Want to stay updated on the latest in #Parkinsons? Our Phase 2 #ClinicalTrial results for solengepras, featured in The Lancet’s eClinicalMedicine, were published in an article by Parkinson's News Today. Read the full story here. parkinsonsnewstoday.com/news/parkinson…

At Cerevance, we are focused on transforming the lives of those with Alzheimer’s disease through the development of cell-type specific treatments for CNS disorders. This National Alzheimer’s Awareness Month, join us in raising awareness about this disease.

Today marks an exciting milestone for Cerevance with the release of positive data from our Phase 1 study of CVN293, a KCNK13 inhibitor, in healthy volunteers. For more details on this important milestone, read the press release here: globenewswire.com/en/news-releas…

We're very pleased to share that we have dosed the first patient in our pivotal Phase 3 ARISE trial of solengepras (CVN424) for the potential treatment of Parkinson's Disease. Read the full press release to learn more about this important milestone: globenewswire.com/news-release/2…

We look forward to presenting our latest research in the coming weeks at #ADPD2025 and #AAN2025. Read about our presentations: bit.ly/3DVbHVG

Interested in learning more about our investigational treatment for Parkinson’s disease? Join us at #ADPD2025, as we present findings from our Phase 2 monotherapy trial. Learn more about on our presentation: bit.ly/4iWFb50

This #ParkinsonsAwarenessMonth, join us in supporting ongoing research to address the unmet needs of individuals impacted by Parkinson’s. Discover more about our Phase 3 ARISE trial of solengepras, our non-dopaminergic treatment option: bit.ly/41Taw2m

We’re back from #ADPD2025, where lead investigator Dr. Aaron Ellenbogen presented our Phase 2 ASCEND monotherapy trial results of solengepras, our investigational treatment for individuals with early, untreated #ParkinsonsDisease. Learn more: bit.ly/4iWFb50

Join us at #AAN2025 to hear about our latest research advancements in the #neurodegenerative disease space. For more details on what we’ll be presenting: bit.ly/42n4ztm

We had a great time presenting our latest #neuroinflammatory and #neurodegerative research at #AANAM last week. Thank you to everyone who joined our poster sessions to learn more about our investigational therapies, solengepras and CVN293. #ICYMI: bit.ly/42n4ztm

Solengepras, our investigational, non-dopaminergic therapy for #ParkinsonsDisease offers a novel approach to treating both motor and non-motor functions while mitigating the side effects commonly associated with the current standard of care. Learn more: bit.ly/41Taw2m

Our investigational CVN293 is a highly selective oral inhibitor targeting KCNK13, a novel intervention point for disorders driven by #neuroinflammation, like obesity. Learn about our plans to advance this potential treatment option for various conditions: bit.ly/3GWvdm3

Interested in learning more about our novel, non-dopaminergic approach for treating Parkinson’s disease? Read about our investigational therapy, solengepras, and the steps we’re taking to bring this treatment option to the #PD community: bit.ly/3Hfabza